Securities Code: 002653
Securities Abbreviation: Hansoh Pharma
Announcement No.: 2026-080
Hansoh Pharmaceutical Group Co., Ltd.
Announcement on the Approval and Listing of the Innovative Drug Compound Bosutinib Tablets
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.
Hansoh Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") learned through an inquiry on the official website of the National Medical Products Administration (hereinafter referred to as the "NMPA") on July 23, 2026, that the NMPA has approved the listing of the Class 1 innovative drug Compound Bosutinib Tablets applied for by the Company. The relevant situation is hereby announced as follows:
I. Basic Information on the Drug and Application
Drug Name: Compound Bosutinib Tablets
Acceptance Number: CXHS2600002
Application Matter: Drug Registration (Domestic Production)
Registration Category: Class 1 Chemical Drug
Dosage Form: Tablets
Specification: 100mg (calculated as C26H27D3N2O3)
Indication: This product is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy.
II. Introduction to the R&D Project